NR4A2
NR4A2 (Nuclear receptor subfamily 4 group A member 2) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma.
Overview
Transcriptional regulator which is important for the differentiation and maintenance of meso-diencephalic dopaminergic (mdDA) neurons during development. It is crucial for expression of a set of genes such as SLC6A3, SLC18A2, TH and DRD2 which are essential for development of mdDA neurons.
CIViC holds 3 clinical evidence items and 0 assertions across 1 variant, naming Gemcitabine and C-DIM 12.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · NR4A2 (Nuclear receptor subfamily 4 group A member 2) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma.
- 1 · What it is
NR4A2 (Nuclear receptor subfamily 4 group A member 2) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma.
- 2 · What goes wrong in cancer
Transcriptional regulator which is important for the differentiation and maintenance of meso-diencephalic dopaminergic (mdDA) neurons during development.
- 3 · How drugs use it
No product in this corpus aims at NR4A2 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
External identifiers
Sources: HGNC HGNC:7981 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P43354 (protein name, function text, keywords and locations (REST API)); CIViC gene NR4A2 (3 evidence items, 0 assertions, 1 variants; diseases: Pancreatic Ductal Adenocarcinoma (GraphQL API, CC0))
Biology
Transcriptional regulator which is important for the differentiation and maintenance of meso-diencephalic dopaminergic (mdDA) neurons during development. It is crucial for expression of a set of genes such as SLC6A3, SLC18A2, TH and DRD2 which are essential for development of mdDA neurons. Location: Cytoplasm; Nucleus (UniProt). Locus 2q24.1 (HGNC).
- Pancreatic ductal adenocarcinoma: CIViC evidence names this disease
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 2 therapies; CIViC holds 3 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"NR4A2" OR ABSTRACT:"NR4A2" OR TITLE:"nuclear receptor subfamily 4 group A member 2" OR ABSTRACT:"nuclear receptor subfamily 4 group A member 2" OR TITLE:"Nuclear receptor subfamily 4 group A member 2" OR ABSTRACT:"Nuclear receptor subfamily 4 group A member 2" OR TITLE:"TINUR" OR ABSTRACT:"TINUR" OR TITLE:"RNR1" OR ABSTRACT:"RNR1" OR TITLE:"HZF-3" OR ABSTRACT:"HZF-3") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about NR4A2, not a curated reading list.